Radiographic and Clinical Outcomes of PureGen in Posterior Lumbar (PLIF) and Transforaminal Interbody Fusion (TLIF)

NCT01293981 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2016-01-20

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of PureGen Osteoprogenitor Cell Allograft in patients undergoing Posterior Lumbar or Transforaminal Interbody Fusion.

Conditions

  • Lumbar Degenerative Disc Disease

Interventions

BIOLOGICAL

PureGen Osteoprogenitor Cell Allograft

PureGen Osteoprogenitor Cell Allograft.

Sponsors & Collaborators

  • Alphatec Spine, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01293981 on ClinicalTrials.gov